{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-198588","form_type":"8-K","ticker":"CUE","cik":"0001645460","company_name":"Cue Biopharma, Inc.","filed_at":"2026-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.651471+00:00","generated_at":"2026-05-15T00:19:56.302504+00:00","sec_items":["1.01","3.02","5.02","8.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Cue Biopharma licenses ex-China rights to anti-IgE mAb Ascendant-221; raises $30M; appoints new CEO","bullets":["License with Ascendant Health Sciences: $15M upfront, up to $676.5M milestones, tiered high-single-to-low-double-digit royalties on ex-China sales.","Concurrent private placement raises ~$28M net via pre-funded warrants and warrants at $11.00/unit to accredited investors including new CEO.","New CEO Dr. Shao-Lee Lin appointed; participates in the private placement.","Ascendant receives pre-funded warrants for 551,724 shares at $0.001; total potential dilution from warrants exceeds 4.6M shares.","Company to seek stockholder approval for share issuances under Nasdaq rules; special meeting within 90 days."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-198588","json":"https://secwatch.observer/filing/0001193125-26-198588.json","markdown":"https://secwatch.observer/filing/0001193125-26-198588.md","text":"https://secwatch.observer/filing/0001193125-26-198588.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645460/000119312526198588/0001193125-26-198588-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645460/000119312526198588/d128047d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T00:19:56.302504+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"78155b8f5d85f9e768fa42502297006f696d8f3f","claim":"Cue Biopharma, Inc. issued up to 551,724 shares of common stock of warrant to Ascendant Health Sciences Ltd..","evidence_excerpt":"the Company agreed to issue to the Licensor at an initial closing (the “Initial Closing”) pre-funded warrants (the “Initial Closing Pre-Funded Warrants”) to purchase up to 551,724 shares of common stock, $0.001 par value per share, of the Company (the “Common Stock”), as partial consideration for the license and rights granted under the License Agreement.","evidence_source":"SEC 8-K Item 3.02/3.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/1645460/000119312526198588/0001193125-26-198588-index.htm","confidence":0.9,"family_label":"Equity Issuances","details":[{"label":"Security","value":"warrant"},{"label":"Shares","value":"up to 551,724 shares of common stock"},{"label":"Purchaser","value":"Ascendant Health Sciences Ltd."}],"fact_type":"equity_issuance"},{"claim_id":"b095ecb5b5","claim":"Shao-Lee Lin was appointed as Member of the Board at Cue Biopharma, Inc..","evidence_excerpt":"On April 27, 2026, the Board appointed Dr. Shao-Lee Lin as the Company’s President and Chief Executive Officer and as a member of the Board, effective as of her commencement of employment with the Company, which began on April 30, 2026","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1645460/000119312526198588/0001193125-26-198588-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Member of the Board"}],"fact_type":"executive_change"},{"claim_id":"c2f42d2507","claim":"Shao-Lee Lin was appointed as President and Chief Executive Officer at Cue Biopharma, Inc..","evidence_excerpt":"On April 27, 2026, the Board appointed Dr. Shao-Lee Lin as the Company’s President and Chief Executive Officer and as a member of the Board, effective as of her commencement of employment with the Company, which began on April 30, 2026","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1645460/000119312526198588/0001193125-26-198588-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"ec92d8b396","claim":"Lucinda Warren resigned as Interim President and Chief Executive Officer at Cue Biopharma, Inc..","evidence_excerpt":"Dr. Lin will succeed Lucinda Warren whose resignation as Interim President and Chief Executive Officer was effective as of April 30, 2026","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1645460/000119312526198588/0001193125-26-198588-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Interim President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"4d29237f553cc54e9d85192eea863e6eac0d5479","claim":"Cue Biopharma, Inc. entered into License Agreement with Ascendant Health Sciences Ltd. valued at $15.0 million as the upfront payment, up to an aggregate of $676.5 million in additional potential m (effective 2026-04-30).","evidence_excerpt":"On April 30, 2026, Cue Biopharma, Inc. (the “Company”) entered into a License Agreement (the “License Agreement”) with Ascendant Health Sciences Ltd., a Cayman Limited Company (the “Licensor”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1645460/000119312526198588/0001193125-26-198588-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Ascendant Health Sciences Ltd."},{"label":"Value","value":"$15.0 million as the upfront payment, up to an aggregate of $676.5 million in additional potential m"},{"label":"Effective","value":"2026-04-30"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}